11.010
11.01 (0%)
As of Dec 20, 2024
Delcath Systems, Inc. [DCTH]
Source:
Company Overview
Delcath Systems, Inc is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, is a drug/device combination product designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Country | United States |
Headquarters | new york, new york |
Phone Number | (212) 489-2100 |
Industry | manufacturing |
CEO | Gerard Michel |
Website | delcath.com |